

September 18, 2018

Cell Innovation Partners Limited

Investment in HistoCell, S.L., a Spanish Clinical-Stage Biopharmaceutical Company, Developing Cell Therapy Products for the Treatment of Acute Spinal Cord Injury and Acute Respiratory Distress Syndrome

Cell Innovation Partners Limited (hereinafter, "CIP") has invested € 1 million in HistoCell, S.L. (hereinafter, "HistoCell") (Headquarters: Bilbao, Spain, CEO: Dr. Julio Font) through Cell Innovation Partners, L.P.. HistoCell develops cell therapy products for the treatment of multiple diseases, including Acute Spinal Cord Injury and Acute Respiratory Distress Syndrome (hereinafter, "ARDS"). This investment is part of a € 3 million financing round that will be used to progress the development of the pipeline products.

HistoCell develops HC016, adipose tissue-derived mesenchymal stem cells that are pre-conditioned with a proprietary protocol during the manufacturing process. Thanks to this process, HC016 is expected to exert higher therapeutic efficacy compared with traditional mesenchymal stem cell products.

In collaboration with Ferrer, the 3rd largest pharmaceutical company in Spain, HC016 is currently in a Phase 1/2 clinical study for the treatment of Acute Spinal Cord Injury in Spain to demonstrate safety and potential efficacy. HistoCell is also preparing to initiate a Phase 1/2 clinical study for the treatment of ARDS in Spain.

Traumatic spinal cord injury resulting from traffic accidents or sports injuries produces damage in the nervous tissue, causing permanent tetraplegia or paraplegia in severe cases. In Japan, the incidence of this is estimated to be approximately 5,000 cases per year. It is a serious injury with no effective treatment. Patients undergo rehabilitation, but they continue to experience difficulties in their lives in society.

ARDS occurs in patients with severe pneumonia or sepsis, whose lungs are flooded with fluid, resulting in difficulty with the lung's gas exchange and decline into respiratory distress. In Japan, the incidence of this is estimated to be approximately 10,000 cases per year. It is a serious syndrome with no effective drug therapy. Although patients are treated with mechanical ventilation in the intensive care unit, the mortality rate is between 30% and 60%.

Additionally, due to HC016's potential to treat multiple diseases, HistoCell is researching the possibility of using HC016 for the treatment of Critical Limb Ischemia.

CIP will support HistoCell to cultivate business partners in Japan and will continue to contribute to the development of regenerative medicine through the provision of funds to regenerative medicine and stem cell venture companies.

Overview of HistoCell S.L.

Establishment: 2004

Business: Development of allogeneic cell therapy products for the treatment of multiple diseases including Acute Spinal Cord Injury and ARDS.

Headquarters: Bilbao, Spain

CEO: Dr. Julio Font

URL: <http://www.histocell.com>**Overview of Phase 1/2 to evaluate safety and efficacy in patients with acute spinal cord injury:**URL: <https://clinicaltrials.gov/ct2/show/record/NCT02917291>**Contact information:**

Cell Innovation Partners Limited

<http://www.cell-ip.com/en>

Kazunobu Nishimura

Email: contact@cell-ip.com